01 9Sabril
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 126
2019 Revenue in Millions : 138
Growth (%) : -8
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 100
2020 Revenue in Millions : 124
Growth (%) : -15
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 92
2021 Revenue in Millions : 100
Growth (%) : -9
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 48
2022 Revenue in Millions : 92
Growth (%) : -47
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 107
2014 Revenue in Millions : 148
Growth (%) : 38%
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : 35%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 257
2016 Revenue in Millions : 228
Growth (%) : 12
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 201
2017 Revenue in Millions : 226
Growth (%) : -11%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 127
2018 Revenue in Millions : 201
Growth (%) : -37
LOOKING FOR A SUPPLIER?